welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
status: completed
purpose:This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
intervention: CRD007
mechanism of action: Non-steroidal agent to decrease inflammation
results: https://clinicaltrials.gov/ct2/show/results/NCT01540604
last updated: November 22, 2018
rareRelated
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsThis study is designed to assess the eff...
-
Safety and Efficacy of P-188 NF in DMD PatientsThis is an open-label study to evaluate ...
-
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
-
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...
-
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...